—
C+
C+ The full Closelooknet — membership. Open the C+ overview

Virbac SA (VIRP.PA) — the peer cohort

As of 2026-10-07 — scores re-bake nightly. Cohort = shared Closelooknet index membership first, then sector. Diary readings, not advice.

Virbac SA ranks 10 of 11 in its cohort on the Closelooknet composite (48/100) — the cohort is led by BB Biotech AG at 74/100.

NameCompositeMomentumQualityValuationSignalOff 52w high
VIRP.PA Virbac SA 48 36 54 63 warn 18%
LLY Eli Lilly and Company 64 70 92 30 bull 10.5%
ORNAV.HE Orion Oyj A 62 82 85 34 ok 1.9%
ORNBV.HE Orion Oyj B 62 82 85 34 ok 1.9%
AMGN Amgen Inc 56 79 86 42 bear 9.9%
NVO Novo Nordisk A/S 55 25 87 75 bear 39.4%
EL.PA EssilorLuxottica S. A. 45 8 49 59 bear 53.6%
BION.SW BB Biotech AG 74 63 96 81 info 12.3%
DXCM DexCom Inc 66 83 81 38 bear 9.9%
ANN.AU Ansell Ltd 64 95 49 54 ok 0.9%
ONC BeiGene, Ltd. 64 81 65 32 ok 5.5%

Scores are relative readings across the Closelooknet coverage universe — methodology in the company-scoring explainer. Signal lights come from the nightly signal board.

FAQ · from the current data · as of 2026-10-07

Quick answers

Who are Virbac SA's peers in the Closelooknet universe?

The cohort is drawn from shared Closelooknet index membership first, then sector: Eli Lilly and Company (LLY), Orion Oyj A (ORNAV.HE), Orion Oyj B (ORNBV.HE), Amgen Inc (AMGN), Novo Nordisk A/S (NVO), EssilorLuxottica S. A. (EL.PA), BB Biotech AG (BION.SW), DexCom Inc (DXCM) and others.

How does VIRP.PA score against its peers?

Virbac SA's composite reads 48/100, ranking 10 of 11 in its cohort as of 2026-10-07; the cohort's highest composite is BB Biotech AG at 74/100. Closelooknet scores are research diary readings, not ratings or advice.

Related in the Closelooknet universe

then Drug Manufacturers - General, then Healthcare. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.